Back to Search Results
Image Place holder

Claudio Anasetti, MD

 
Specialty: Blood and Marrow Transplant and Cellular Immunotherapy
Sub Specialty: Medical Oncology
Program: Blood and Marrow Transplant and Cellular Immunotherapy

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Leukemia, Multiple Myeloma-Plasma Cell Tumor, Myelodysplastic Syndromes (MDS)

Dr. Claudio Anasetti is Emeritus Member of the Department of Blood & Marrow Transplantation and Cellular Immunotherapy at the Moffitt Cancer Center and Research Institute in Tampa, Florida, U.S.A. In 1980, Dr. Anasetti graduated as M.D. cum laude from the University of Perugia School of Medicine. He trained in Internal Medicine at the University of Perugia, in Italy. He pursued training as Fellow in Immunology at the Children’s Memorial Hospital, with Dr. Robert A. Good in Oklahoma City, Oklahoma, and Fellow in Oncology, at the University of Washington and the Fred Hutchinson Cancer Research Center with Dr. E. Donnall Thomas (Nobel Prize recipient), in Seattle, Washington. Dr. Anasetti established his research immunology laboratory with Drs. John A. Hansen and Paul J. Martin at the Fred Hutchinson Cancer Research Center, became the leader of the first and largest unrelated donor marrow transplant program in the world and developed his academic career to the rank of Full Member at the Fred Hutchinson and Full Professor at University of Washington, in Seattle, Washington. Dr. Anasetti’s lab was the first to identify the CD28 pathway as key for establishing immunological tolerance in humans. Also, Dr. Anasetti established guiding principles for the selection of partially matched related and unrelated donors that have stood for the last 35 years. In 2004, Dr. Anasetti moved from Seattle to Tampa in Florida, where he expanded a small transplant program to develop into one of the top 5 programs by size and reputation in the U.S.A. In 2015 at the Moffitt Cancer Center, Dr. Anasetti launched the Immune Cell Therapy Program that was instrumental for the clinical development and later F.D.A. approval of the first CD19-specific, chimeric antigen receptor T cell for the treatment of relapsed or refractory lymphoma. Dr. Anasetti serves currently on the data and safety monitoring boards of Kite and Allogene, companies that are developing CAR T cells for cancer immunotherapy. To date, Dr. Anasetti has co-authored over 500 peer-reviewed publications and book chapters. A past president of the American Society of Blood and Marrow Transplantation, Dr. Anasetti has been a charter member of the National Institutes of Health Clinical Oncology Study Section, and chair of the Strategic Capacity Initiative Physician Workforce Group for the National Marrow Donor Program. In addition, Dr. Anasetti is on several national editor boards and a journal reviewer for numerous professional journals, including the New England Journal of Medicine. 


Education & Training

Board Certification:

  • Internal Medicine - Medical Oncology

Fellowship:

  • Children's Memorial Hospital, Oklahoma City - Immunology
  • University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA - Oncology

Residency:

  • University of Perugia, Italy - Internal Medicine

Medical School:

  • University of Perugia, Italy - MD
Awards
Start Year: 2005 End Year: 2009 Scientific Chair, 2006 Meeting, Sponsor: ASBMT/CIBMIT
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J. Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial. Transplant Cell Ther. 2023 Mar.29(3):208.e1-208.e6. Pubmedid: 36584941. Pmcid: PMC9992261.
  • Bashir Q, Nishihori T, Pasquini MC, Martens MJ, Wu J, Alsina M, Anasetti C, Brunstein C, Dawson P, Efebera Y, Gasparetto C, Geller N, Giralt S, Hall AC, Koreth J, McCarthy P, Scott E, Stadtmauer EA, Vesole DH, Hari P. A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial. Transplant Cell Ther. 2023 Jun.29(6):358.e1-358.e7. Pubmedid: 35840087.
  • Boucher JC, Yu B, Li G, Shrestha B, Sallman D, Landin AM, Cox C, Karyampudi K, Anasetti C, Davila ML, Bejanyan N. Large Scale Ex Vivo Expansion of γδ T cells Using Artificial Antigen-presenting Cells. J Immunother. 2023 Jan.46(1):5-13. Pubmedid: 36378147. Pmcid: PMC9722378.
  • Pidala J, Anasetti C. Fine-tuning alloreactivity against HLA-DP to control leukemia with tolerable graft-versus-host disease. Haematologica. 2023 Feb.108(2):301-302. Pubmedid: 35546302. Pmcid: PMC9890004.
  • Walton K, Walker K, Riddle M, Koehn BH, Reff J, Sagatys EM, Linden MA, Pidala J, Kim J, Lee MC, Kiluk JV, Hui JYC, Yun SY, Xing Y, Stefanski H, Lawrence HR, Lawrence NJ, Tolar J, Anasetti C, Blazar BR, Sebti SM, Betts BC. Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repair. Am J Transplant. 2022 Mar.22(3):717-730. Pubmedid: 34668635. Pmcid: PMC8897228.
  • Lazaryan A, Lee SJ, Arora M, Kim J, Betts BC, Khimani F, Nishihori T, Bejanyan N, Liu H, Kharfan-Dabaja MA, Locke FL, Gonzalez R, Jain MD, Davila ML, Perez LE, Mishra A, Perez Perez A, Balke K, Ayala E, Ochoa L, Castaneda Puglianini O, Faramand RG, Alsina M, Elmariah H, Nieder M, Fernandez H, Anasetti C, Pidala J. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Adv. 2022 Jan.6(1):259-269. Pubmedid: 34649279. Pmcid: PMC8753213.
  • Otoukesh S, Elmariah H, Yang D, Clark MC, Siraj M, Ali H, Mogili K, Arslan S, Nishihori T, Nakamura R, Pidala J, Marcucci G, Forman SJ, Anasetti C, Malki MMA, Bejanyan N. Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2022 Feb.28(2):111.e1-111.e8. Pubmedid: 34844022.
  • Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T, Locke FL, Perez Perez A, Dean E, Mishra A, Perez L, Lazaryan A, Jain MD, Nieder M, Liu H, Faramand R, Hansen D, Alsina M, Ochoa L, Davila M, Anasetti C, Pidala J, Bejanyan N. Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. Transplant Cell Ther. 2021 Nov.27(11):940-948. Pubmedid: 34329754.
  • Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, Spitler K, Faramand R, Bachmeier CA, Dean EA, Cao B, Chavez JC, Shah BD, Lazaryan A, Nishihori T, Hussaini MO, Gonzalez RJ, Mullinax JE, Rodriguez P, Conejo-Garcia J, Anasetti C, Davila ML, Locke FL. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021 May.137(19):2621-2633. Pubmedid: 33512407. Pmcid: PMC8120145.
  • Pidala J, Walton K, Elmariah H, Kim J, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez L, Faramand RG, Davila ML, Nieder ML, Sagatys EM, Holtan SG, Lawrence NJ, Lawrence HR, Blazar BR, Anasetti C, Sebti SM, Betts BC. Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. Clin Cancer Res. 2021 May.27(10):2712-2722. Pubmedid: 33753457. Pmcid: PMC8127396.
  • Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, Alsina M, Kharfan-Dabaja MA, Fernandez H, Nieder ML, Locke FL, Anasetti C, Ayala E. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv. 2021 Mar.5(5):1154-1163. Pubmedid: 33635333. Pmcid: PMC7948297.
  • Hansen DK, Kim J, Thompson Z, Hussaini M, Nishihori T, Ahmad A, Elmariah H, Faramand R, Mishra A, Davila ML, Khimani F, Lazaryan A, Sallman D, Liu H, Perez LE, Fernandez H, Nieder ML, Lancet JE, Pidala JA, Anasetti C, Bejanyan N. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2021 Mar.27(3):256.e1-256.e7. Pubmedid: 33781526. Pmcid: PMC8711732.
  • Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2021 Jun.39(18):1971-1982. Pubmedid: 33905264. Pmcid: PMC8260905.
  • Elmariah H, Naqvi SMH, Kim J, Nishihori T, Mishra A, Perez L, Faramand R, Lazaryan A, Liu HD, Khimani F, Nieder M, Anasetti C, Pidala J, Bejanyan N. Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2021 Jul.56(7):1683-1690. Pubmedid: 33658647.
  • Perez L, Fernandez H, Kharfan-Dabaja M, Khimani F, Betts B, Mishra A, Ayala E, Locke FL, Ochoa-Bayona L, Nieder M, Pidala J, Achille A, Powers J, Sahakian E, Thapa R, Wang X, Anasetti C. A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. Blood Adv. 2021 Jul.5(13):2740-2750. Pubmedid: 34242388. Pmcid: PMC8288668.
  • Bejanyan N, Anasetti C. First-line hypomethylating agents for patients with high risk chronic myelomonocytic leukaemia. Lancet Haematol. 2021 Feb.8(2):e99-e101. Pubmedid: 33513378.
  • Mishra A, Pidala J, Thapa R, Betts BC, Fernandez H, Locke FL, Nishihori T, Perez L, Wang X, Anasetti C, Jim H. Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2021 Dec.56(12):2897-2903. Pubmedid: 34381169.
  • Shrestha B, Walton K, Reff J, Sagatys EM, Tu N, Boucher JC, Li G, Ghafoor T, Felices M, Miller J, Pidala J, Blazar BR, Anasetti C, Betts BC, Davila ML. Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease. J Clin Invest. 2020 Sep.130(9):4652-4662. Pubmedid: 32437331. Pmcid: PMC7456225.
  • Lee Dupuis L, Quinones CM, Ritchie J, Carpenter PA, Bauters T, Yeh RF, Anasetti C, Boelens JJ, Hamerschlak N, Hassan M, Kang HJ, Kanda Y, Paci A, Perales MA, Shaw PJ, Seewaldt VL, Savani BN, Militano O, Pulsipher MA, McCune JS. Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". Biol Blood Marrow Tr. 2020 Sep.26(9):e235-e236. Pubmedid: 32531439.
  • Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, Lee SB, Spitler K, Wang X, Cao B, Pinilla J, Lazaryan A, Khimani F, Shah B, Chavez JC, Nishihori T, Mishra A, Mullinax J, Gonzalez R, Hussaini M, Dam M, Brandjes BD, Bachmeier CA, Anasetti C, Locke FL, Davila ML. Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clin Cancer Res. 2020 Sep.26(18):4823-4831. Pubmedid: 32669372. Pmcid: PMC7501265.
  • Walton K, Fernandez MR, Sagatys EM, Reff J, Kim J, Lee MC, Kiluk JV, Hui JYC, McKenna D, Hupp M, Forster C, Linden MA, Lawrence NJ, Lawrence HR, Pidala J, Pavletic SZ, Blazar BR, Sebti SM, Cleveland JL, Anasetti C, Betts BC. Metabolic reprogramming augments potency of human pSTAT3-inhibited iTregs to suppress alloreactivity. JCI Insight. 2020 May.5(9). Pubmedid: 32255769. Pmcid: PMC7253027.
  • DiMaggio E, Zhou JM, Caddell R, Tombleson R, Perkins J, Anasetti C, Khimani F, Pidala J, Nishihori T, Perez L, Betts B, Fernandez HF, Mishra A. Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2020 Jul.61(7):1678-1687. Pubmedid: 32133897. Pmcid: PMC7771324.
  • Frairia C, Nicolosi M, Shapiro J, Kim J, Betts BC, Fernandez HF, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C. Sole Upfront Therapy with Beclomethasone and Budesonide for Upper Gastrointestinal Acute Graft-versus-Host Disease. Biol Blood Marrow Tr. 2020 Jul.26(7):1303-1311. Pubmedid: 32361010. Pmcid: PMC7771266.
  • Pidala J, Martens M, Anasetti C, Carreras J, Horowitz M, Lee SJ, Antin J, Cutler C, Logan B. Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. JAMA Oncol. 2020 Jan.6(1):e192974. Pubmedid: 31556923. Pmcid: PMC6763979.
  • Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JL, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolanos-Meade J, Howard A, Logan BR, Leifer E, Pritchard TS, Horowitz MM, MacMillan ML. Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood. 2020 Jan.135(2):97-107. Pubmedid: 31738834. Pmcid: PMC6952830.
  • McCune JS, Quinones CM, Ritchie J, Carpenter PA, van Maarsveen E, Yeh RF, Anasetti C, Boelens JJ, Hamerschlak N, Hassan M, Kang HJ, Kanda Y, Paci A, Perales MA, Shaw PJ, Seewaldt VL, Savani BN, Hsieh A, Poon B, Mohty M, Pulsipher MA, Pasquini M, Dupuis LL. Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. Biol Blood Marrow Tr. 2019 Sep.25(9):1890-1897. Pubmedid: 31136799. Pmcid: PMC6755045.
  • Rashidi A, Shanley R, Anasetti C, Waller EK, Scott BL, Blazar BR, Weisdorf DJ. Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD. Bone Marrow Transplant. 2019 Mar.54(3):490-493. Pubmedid: 30171221. Pmcid: PMC6395530.
  • Khimani F, McDonald GB, Shulman HM, Betts B, Locke F, Fernandez H, Anasetti C, Pidala J. Hepatic veno-occlusive disease following sirolimus-based immune suppression. Bone Marrow Transplant. 2019 Jan.54(1):85-89. Pubmedid: 29895929.
  • Repaczki-Jones R, Hrnicek AK, Heissenbuttel A, Devine S, Fernandez H, Anasetti C. Defining Competency to Empower Blood and Marrow Transplant and Cellular Immunotherapy Quality Management Professionals in Healthcare. Biol Blood Marrow Tr. 2019 Jan.25(1):179-182. Pubmedid: 30138698.
  • Waller EK, Logan BR, Fei M, Lee SJ, Confer D, Howard A, Chandrakasan S, Anasetti C, Fernando SM, Giver CR. Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSF-mobilized stem cell transplantation. Blood Adv. 2019 Aug.3(15):2250-2263. Pubmedid: 31345792. Pmcid: PMC6693008.
  • Rashidi A, Luo X, Cooley S, Anasetti C, Waller EK, Brunstein CG, Cichocki F, Weisdorf DJ, Miller JS. The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples. Blood Adv. 2019 Aug.3(16):2465-2469. Pubmedid: 31427278. Pmcid: PMC6712525.
  • Rashidi A, Shanley R, Yohe SL, Thyagarajan B, Curtsinger J, Anasetti C, Waller EK, Scott BL, Blazar BR, Weisdorf DJ. Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTN-0201 and -0901 samples. Brit J Haematol. 2018 Sep.182(6):887-894. Pubmedid: 30004111. Pmcid: PMC6128755.
  • Perez L, Fernandez H, Horna P, Riches M, Locke F, Field T, Powers J, Sahakian E, Villagra A, Mishra A, Betts B, Kharfan-Dabaja M, Beato F, Ochoa-Bayona L, Pidala J, Anasetti C. Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. Bone Marrow Transplant. 2018 Nov.53(11):1434-1444. Pubmedid: 29670210. Pmcid: PMC7771280.
  • Pidala J, Beato F, Kim J, Betts B, Jim H, Sagatys E, Levine JE, Ferrara JL, Ozbek U, Ayala E, Davila M, Fernandez HF, Field T, Kharfan-Dabaja MA, Khaira D, Khimani F, Locke FL, Mishra A, Nieder M, Nishihori T, Perez L, Riches M, Anasetti C. IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica. 2018 Mar.103(3):531-539. Pubmedid: 29242294. Pmcid: PMC5830373.
  • Kharfan-Dabaja MA, Sheets K, Kumar A, Murthy HS, Nishihori T, Tsalatsanis A, Mina A, Mathews J, Ayala E, Chavez J, Perez LE, Betts BC, Anasetti C, Pidala J. Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. Brit J Haematol. 2018 Mar.180(6):854-862. Pubmedid: 29345306.
  • Locke FL, Anasetti C. Off-the-shelf TCR for graft-versus-leukemia without GVHD. Blood. 2018 Jan.131(1):5-7. Pubmedid: 29301771. Pmcid: PMC5755047.
  • Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts BC, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona JL, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja MA. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. Biol Blood Marrow Tr. 2018 Feb.24(2):400-405. Pubmedid: 29032266.
  • Betts BC, Bastian D, Iamsawat S, Nguyen H, Heinrichs JL, Wu Y, Daenthanasanmak A, Veerapathran A, O'Mahony A, Walton K, Reff J, Horna P, Sagatys EM, Lee MC, Singer J, Chang YJ, Liu C, Pidala J, Anasetti C, Yu XZ. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc Natl Acad Sci U S A. 2018 Feb.115(7):1582-1587. Pubmedid: 29382747. Pmcid: PMC5816153.
  • Markow M, Mirza AS, Perez L, Shao H, Horna P, Anasetti C, Sokol L, Hussaini MO. Transformation of T-Cell Acute Lymphoblastic Lymphoma to Peripheral T-Cell Lymphoma: A Report of Two Cases. Case Rep Hematol. 2018 Feb.2018:9191582. Pubmedid: 29682368. Pmcid: PMC5850893.
  • Betts BC, Locke FL, Sagatys EM, Pidala J, Walton K, Menges M, Reff J, Saha A, Djeu JY, Kiluk JV, Lee MC, Kim J, Kang CW, Tang CA, Frieling J, Lynch CC, List A, Rodriguez PC, Blazar BR, Conejo-Garcia JR, Del Valle JR, Hu CA, Anasetti C. Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. Front Immunol. 2018 Dec.9:2887. Pubmedid: 30574153. Pmcid: PMC6291501.
  • Rashidi A, Shanley R, Yohe SL, Thyagarajan B, Curtsinger J, Anasetti C, Waller EK, Miller JS, Blazar BR, Weisdorf DJ. Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples. Bone Marrow Transplant. 2018 Aug.53(8):1069-1071. Pubmedid: 29515246. Pmcid: PMC6064382.
  • Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biol Blood Marrow Tr. 2018 Apr.24(4):726-733. Pubmedid: 29197676. Pmcid: PMC5902420.
  • Bashey A, Zhang MJ, McCurdy SR, St Martin A, Argall T, Anasetti C, Ciurea SO, Fasan O, Gaballa S, Hamadani M, Munshi P, Al Malki MM, Nakamura R, O'Donnell PV, Perales MA, Raj K, Romee R, Rowley S, Rocha V, Salit RB, Solh M, Soiffer RJ, Fuchs EJ, Eapen M. Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2017 Sep.35(26):3002-3009. Pubmedid: 28644773. Pmcid: PMC5590802.
  • Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, Sallman D, Salem KZ, Zhang L, Moscinski L, Fernandez HF, Lancet J, List A, Anasetti C, Padron E. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Nov.17(11):753-758. Pubmedid: 28687222. Pmcid: PMC5675815.
  • Hoogland AI, Nelson AM, Small BJ, Hyland KA, Gonzalez BD, Booth-Jones M, Anasetti C, Jacobsen PB, Jim HSL. The Role of Age in Neurocognitive Functioning among Adult Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Tr. 2017 Nov.23(11):1974-1979. Pubmedid: 28797784. Pmcid: PMC5682195.
  • Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, Ayala E, Locke FL, Riches M, Kharfan-Dabaja M, Fernandez H, Anasetti C. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica. 2017 May.102(5):948-957. Pubmedid: 28104702. Pmcid: PMC5477614.
  • Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. Bone Marrow Transplant. 2017 Mar.52(3):438-444. Pubmedid: 27819684.
  • Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, Shaw BE, Beato F, Laport GG, Nademanee A, Keating A, Socie G, Anasetti C. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2017 Mar.23(3):405-411. Pubmedid: 28007665. Pmcid: PMC6716167.
  • de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017 Mar.129(13):1753-1762. Pubmedid: 28096091. Pmcid: PMC5524528.
  • Locke FL, Anasetti C. Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap. J Immunother Cancer. 2017 Jul.5:59. Pubmedid: 28725432. Pmcid: PMC5514522.
  • Khimani F, Kim J, Chen L, Dean E, Rizk V, Betts B, Nishihori T, Locke F, Mishra A, Perez L, Ayala E, Kharfan-Dabaja M, Nieder M, Fernandez H, Anasetti C, Pidala J. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. Bone Marrow Transplant. 2017 Jul.52(7):1003-1009. Pubmedid: 28368376. Pmcid: PMC7771296.
  • Tram K, Stritesky G, Wadsworth K, Ng J, Anasetti C, Dehn J. Identification of DPB1 Permissive Unrelated Donors Is Highly Likely. Biol Blood Marrow Tr. 2017 Jan.23(1):81-86. Pubmedid: 27989930.
  • Betts BC, Veerapathran A, Pidala J, Yang H, Horna P, Walton K, Cubitt CL, Gunawan S, Lawrence HR, Lawrence NJ, Sebti SM, Anasetti C. Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function. Sci Transl Med. 2017 Jan.9(372). Pubmedid: 28077684. Pmcid: PMC6368389.
  • Murthy H, Anasetti C, Ayala E. Diagnosis and Management of Leukemic and Lymphomatous Meningitis. Cancer Control. 2017 Jan.24(1):33-41. Pubmedid: 28178710.
  • Perez LE, Fernandez H, Ayala E, Beato F, Neuger A, Pidala J, Schell MJ, Anasetti C. Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors. Bone Marrow Transplant. 2017 Apr.52(4):627-629. Pubmedid: 27991896. Pmcid: PMC5382111.
  • Locke FL, Anasetti C. Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap. J Immunother Cancer. 2017 07.5(1):59. Pubmedid: 28716155. Pmcid: PMC5514522.
  • Heinrichs J, Bastian D, Veerapathran A, Anasetti C, Betts B, Yu XZ. Regulatory T-Cell Therapy for Graft-versus-host Disease. J Immunol Res Ther. 2016 Oct.1(1):1-14. Pubmedid: 27722210. Pmcid: PMC5049884.
  • Heinrichs J, Li J, Nguyen H, Wu Y, Bastian D, Daethanasanmak A, Sofi MH, Schutt S, Liu C, Jin J, Betts B, Anasetti C, Yu XZ. CD8(+) Tregs promote GVHD prevention and overcome the impaired GVL effect mediated by CD4(+) Tregs in mice. Oncoimmunology. 2016 Mar.5(6):e1146842. Pubmedid: 27471614. Pmcid: PMC4938369.
  • Burns LJ, Logan BR, Chitphakdithai P, Miller JP, Drexler R, Spellman S, Switzer GE, Wingard JR, Anasetti C, Confer DL. Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201. Biol Blood Marrow Tr. 2016 Jun.22(6):1108-1116. Pubmedid: 27013014. Pmcid: PMC4867293.
  • Pidala J, Anasetti C. Predicting relevant immunogenetic disparities. Blood. 2016 Jul.128(1):12-13. Pubmedid: 27389541. Pmcid: PMC4937356.
  • Kollman C, Spellman SR, Zhang MJ, Hassebroek A, Anasetti C, Antin JH, Champlin RE, Confer DL, DiPersio JF, Fernandez-Viña M, Hartzman RJ, Horowitz MM, Hurley CK, Karanes C, Maiers M, Mueller CR, Perales MA, Setterholm M, Woolfrey AE, Yu N, Eapen M. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016 Jan.127(2):260-267. Pubmedid: 26527675. Pmcid: PMC4713163.
  • Young JH, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, Knust K, Horowitz MM, Confer DL, Dubberke ER, Pergam SA, Marty FM, Strasfeld LM, Brown JW, Langston AA, Schuster MG, Kaul DR, Martin SI, Anasetti C. Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. Biol Blood Marrow Tr. 2016 Feb.22(2):359-370. Pubmedid: 26409243. Pmcid: PMC4716871.
  • Locke FL, Menges M, Nishihori T, Nwoga C, Alsina M, Anasetti C. Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma. Bone Marrow Transplant. 2016 Feb.51(2):291-294. Pubmedid: 26457911. Pmcid: PMC5726387.
  • Lee SJ, Logan B, Westervelt P, Cutler C, Woolfrey A, Khan SP, Waller EK, Maziarz RT, Wu J, Shaw BE, Confer D, Horowitz MM, Anasetti C. Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial. JAMA Oncol. 2016 Dec.2(12):1583-1589. Pubmedid: 27532508. Pmcid: PMC5145732.
  • Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro J, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Tr. 2016 Dec.22(12):2117-2125. Pubmedid: 27660167. Pmcid: PMC5116249.
  • Mishra A, Anasetti C. Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S49-S52. Pubmedid: 27521324.
  • Fu J, Wu Y, Nguyen H, Heinrichs J, Schutt S, Liu Y, Liu C, Jin J, Anasetti C, Yu XZ. T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice. J Immunol. 2016 Apr.196(7):3168-3179. Pubmedid: 26903480. Pmcid: PMC4799777.
  • Tees MT, Betts B, Hillgruber R, Ayala E, Field T, Kharfan-Dabaja MA, Locke F, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C, Fernandez H, Riches ML. New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes?. Bone Marrow Transplant. 2016 09.51(9):1256-1258. Pubmedid: 27088383.
  • Nishihori T, El-Asmar J, Shah B, Hussaini M, Komrokji R, List A, Anasetti C, Kharfan-Dabaja MA. Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic cell transplantation: a single-center experience and a review of the literature. Bone Marrow Transplant. 2015 Oct.50(10):1388-1392. Pubmedid: 26191951.
  • Nelson R, Shapiro JF, Perkins JB, Kim J, Nishihori T, Pidala J, Ayala E, Locke FL, Field T, Mishra A, Riches M, Betts B, Perez L, Yue B, Ochoa-Bayona JL, Alsina M, Fernandez H, Anasetti C, Kharfan-Dabaja MA. Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. Bone Marrow Transplant. 2015 Nov.50(11):1487-1489. Pubmedid: 26301969. Pmcid: PMC4863975.
  • Locke FL, Menges M, Veerapathran A, Coppola D, Gabrilovich D, Anasetti C. Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma. J Immunother Cancer. 2015 May.3:20. Pubmedid: 25992291. Pmcid: PMC4437443.
  • Pidala J, Bloom GC, Eschrich S, Sarwal M, Enkemann S, Betts BC, Beato F, Yoder S, Anasetti C. Tolerance associated gene expression following allogeneic hematopoietic cell transplantation. PLoS One. 2015 Mar.10(3):e0117001. Pubmedid: 25774806. Pmcid: PMC4361657.
  • Ayala E, Figueroa J, Perkins J, Kim J, Yue B, Riches M, Nishihori T, Locke F, Anasetti C, Kharfan-Dabaja MA. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2015 Jun.15(6):335-340. Pubmedid: 25659459.
  • Pidala J, Kim J, Betts BC, Alsina M, Ayala E, Fernandez HF, Field T, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. Biol Blood Marrow Tr. 2015 Jun.21(6):1074-1082. Pubmedid: 25805300. Pmcid: PMC5757506.
  • Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. Haematologica. 2015 Jul.100(7):970-977. Pubmedid: 25840599. Pmcid: PMC4486232.
  • Li J, Heinrichs J, Haarberg K, Semple K, Veerapathran A, Liu C, Anasetti C, Yu XZ. HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease. J Immunol. 2015 Jul.195(2):717-725. Pubmedid: 26048147. Pmcid: PMC4491008.
  • Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, Chen J, Maziarz RT, McCarthy PL, Nakamura R, Ratanatharathorn V, Vij R, Champlin RE. Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. Biol Blood Marrow Tr. 2015 Jan.21(1):55-59. Pubmedid: 25255165. Pmcid: PMC4272909.
  • McCune JS, Vicini P, Salinger DH, O'Donnell PV, Sandmaier BM, Anasetti C, Mager DE. Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration. Cancer Chemother Pharmacol. 2015 Jan.75(1):67-75. Pubmedid: 25374408. Pmcid: PMC4282607.
  • Fu J, Wang D, Yu Y, Heinrichs J, Wu Y, Schutt S, Kaosaard K, Liu C, Haarberg K, Bastian D, McDonald DG, Anasetti C, Yu XZ. T-bet is critical for the development of acute graft-versus-host disease through controlling T cell differentiation and function. J Immunol. 2015 Jan.194(1):388-397. Pubmedid: 25404360. Pmcid: PMC4314960.
  • Betts B, Anasetti C, Pidala J. Biomarkers for GVHD prognosis. Lancet Haematol. 2015 Jan.2(1):e4-e5. Pubmedid: 26687427.
  • Appelbaum FR, Anasetti C, Antin JH, Atkins H, Davies S, Devine S, Giralt S, Heslop H, Laport G, Lee SJ, Logan B, Pasquini M, Pulsipher M, Stadtmauer E, Wingard JR, Horowitz MM. Blood and marrow transplant clinical trials network state of the Science Symposium 2014. Biol Blood Marrow Tr. 2015 Feb.21(2):202-224. Pubmedid: 25445636. Pmcid: PMC4426907.
  • Nishihori T, Komrokji R, Shain K, Anasetti C. Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome. Bone Marrow Transplant. 2015 Feb.50(2):296-297. Pubmedid: 25330222.
  • Betts BC, Sagatys EM, Veerapathran A, Lloyd MC, Beato F, Lawrence HR, Yue B, Kim J, Sebti SM, Anasetti C, Pidala J. CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response. J Leukoc Biol. 2015 Apr.97(4):807-819. Pubmedid: 25663681. Pmcid: PMC4370048.
  • Anasetti C. Use of alternative donors for allogeneic stem cell transplantation. Hematology Am Soc Hematol Educ Program. 2015.2015:220-224. Pubmedid: 26637725.
  • Chavez JC, Kharfan-Dabaja MA, Kim J, Yue B, Dalia S, Pinilla-Ibarz J, Anasetti C, Locke FL. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Leuk Res. 2014 Oct.38(10):1165-1172. Pubmedid: 24889511. Pmcid: PMC4625795.
  • Pidala J, Lee SJ, Ahn KW, Spellman S, Wang HL, Aljurf M, Askar M, Dehn J, Fernandez Viña M, Gratwohl A, Gupta V, Hanna R, Horowitz MM, Hurley CK, Inamoto Y, Kassim AA, Nishihori T, Mueller C, Oudshoorn M, Petersdorf EW, Prasad V, Robinson J, Saber W, Schultz KR, Shaw B, Storek J, Wood WA, Woolfrey AE, Anasetti C. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood. 2014 Oct.124(16):2596-2606. Pubmedid: 25161269. Pmcid: PMC4199961.
  • Nishihori T, Perkins J, Mishra A, Komrokji R, Kim J, Kharfan-Dabaja MA, Perez L, Lancet J, Fernandez H, List A, Anasetti C, Field T. Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome. Biol Blood Marrow Tr. 2014 Jun.20(6):776-780. Pubmedid: 24534108.
  • Kunter G, Perkins JB, Pidala J, Nishihori T, Kharfan-Dabaja MA, Field T, Fernandez H, Perez L, Locke F, Ayala E, Tomblyn M, Ochoa-Bayona JL, Betts B, Nieder M, Anasetti C. Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone Marrow Transplant. 2014 Jan.49(1):11-16. Pubmedid: 23995098.
  • Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C, Arcese W, Barker JN, Baxter-Lowe LA, Brown M, Fernandez-Vina MA, Freeman J, He W, Paolo Iori A, Horowitz MM, Locatelli F, Marino S, Maiers M, Michel G, Sanz GF, Gluckman E, Rocha V. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014 Jan.123(1):133-140. Pubmedid: 24141369. Pmcid: PMC3879902.
  • Switzer GE, Bruce JG, Harrington D, Haagenson M, Drexler R, Foley A, Confer D, Bishop M, Anderlini P, Rowley S, Leitman SF, Anasetti C, Wingard JR. Health-related quality of life of bone marrow versus peripheral blood stem cell donors: a prespecified subgroup analysis from a phase III RCT-BMTCTN protocol 0201. Biol Blood Marrow Tr. 2014 Jan.20(1):118-127. Pubmedid: 24184336. Pmcid: PMC3978600.
  • Betts BC, Veerapathran A, Pidala J, Yu XZ, Anasetti C. STAT5 polarization promotes iTregs and suppresses human T-cell alloresponses while preserving CTL capacity. J Leukoc Biol. 2014 Feb.95(2):205-213. Pubmedid: 24068731. Pmcid: PMC3896660.
  • Waller EK, Logan BR, Harris WA, Devine SM, Porter DL, Mineishi S, McCarty JM, Gonzalez CE, Spitzer TR, Krijanovski OI, Linenberger ML, Woolfrey A, Howard A, Wu J, Confer DL, Anasetti C. Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201. J Clin Oncol. 2014 Aug.32(22):2365-2372. Pubmedid: 24982459. Pmcid: PMC4180368.
  • Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, Sullivan D, Jim HS, Anasetti C, Alsina M. Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. Bone Marrow Transplant. 2013 Sep.48(9):1179-1184. Pubmedid: 23542223. Pmcid: PMC4500071.
  • Yu Y, Wang D, Kaosaard K, Liu C, Fu J, Haarberg K, Anasetti C, Beg AA, Yu XZ. c-Rel is an essential transcription factor for the development of acute graft-versus-host disease in mice. Eur J Immunol. 2013 Sep.43(9):2327-2337. Pubmedid: 23716202. Pmcid: PMC3940138.
  • Veerapathran A, Pidala J, Beato F, Betts B, Kim J, Turner JG, Hellerstein MK, Yu XZ, Janssen W, Anasetti C. Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease. Blood. 2013 Sep.122(13):2251-2261. Pubmedid: 23908471. Pmcid: PMC3785121.
  • Haarberg KM, Li J, Heinrichs J, Wang D, Liu C, Bronk CC, Kaosaard K, Owyang AM, Holland S, Masuda E, Tso K, Blazar BR, Anasetti C, Beg AA, Yu XZ. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice. Blood. 2013 Oct.122(14):2500-2511. Pubmedid: 23908466. Pmcid: PMC3790515.
  • Pidala J, Wang T, Haagenson M, Spellman SR, Askar M, Battiwalla M, Baxter-Lowe LA, Bitan M, Fernandez-Viña M, Gandhi M, Jakubowski AA, Maiers M, Marino SR, Marsh SG, Oudshoorn M, Palmer J, Prasad VK, Reddy V, Ringden O, Saber W, Santarone S, Schultz KR, Setterholm M, Trachtenberg E, Turner EV, Woolfrey AE, Lee SJ, Anasetti C. Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. Blood. 2013 Nov.122(22):3651-3658. Pubmedid: 23982174. Pmcid: PMC3837514.
  • Wang D, Yu Y, Haarberg K, Fu J, Kaosaard K, Nagaraj S, Anasetti C, Gabrilovich D, Yu XZ. Dynamic change and impact of myeloid-derived suppressor cells in allogeneic bone marrow transplantation in mice. Biol Blood Marrow Tr. 2013 May.19(5):692-702. Pubmedid: 23376089. Pmcid: PMC4011929.
  • Fernández-Viña MA, Klein JP, Haagenson M, Spellman SR, Anasetti C, Noreen H, Baxter-Lowe LA, Cano P, Flomenberg N, Confer DL, Horowitz MM, Oudshoorn M, Petersdorf EW, Setterholm M, Champlin R, Lee SJ, de Lima M. Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. Blood. 2013 May.121(22):4603-4610. Pubmedid: 23596045. Pmcid: PMC3668493.
  • Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, Perez L, Perkins J, Shapiro J, Tate C, Tomblyn M, Anasetti C. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant. 2013 Mar.48(3):346-350. Pubmedid: 22863723. Pmcid: PMC4500122.
  • Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. Biol Blood Marrow Tr. 2013 Jul.19(7):1087-1093. Pubmedid: 23632090. Pmcid: PMC4667782.
  • Denzen EM, Majhail NS, Stickney Ferguson S, Anasetti C, Bracey A, Burns L, Champlin R, Chell J, Leather H, Lill M, Maziarz RT, Medoff E, Neumann J, Schmit-Pokorny K, Snyder EL, Wiggins L, Yolin Raley DS, Murphy EA. Hematopoietic cell transplantation in 2020: summary of year 2 recommendations of the National Marrow Donor Program's System Capacity Initiative. Biol Blood Marrow Tr. 2013 Jan.19(1):4-11. Pubmedid: 23078785. Pmcid: PMC3617925.
  • Pidala J, Craig BM, Lee SJ, Majhail N, Quinn G, Anasetti C. Practice variation in physician referral for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2013 Jan.48(1):63-67. Pubmedid: 22705801. Pmcid: PMC3549547.
  • Yu Y, Cho HI, Wang D, Kaosaard K, Anasetti C, Celis E, Yu XZ. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms. J Immunol. 2013 Feb.190(4):1873-1881. Pubmedid: 23315072. Pmcid: PMC3563723.
  • Anasetti C, Logan BR, Confer DL. Peripheral-blood versus bone marrow stem cells. N Engl J Med. 2013 01.368(3):288. Pubmedid: 23323911.
  • Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012 Oct.367(16):1487-1496. Pubmedid: 23075175. Pmcid: PMC3816375.
  • Boucher K, Parquet N, Widen R, Shain K, Baz R, Alsina M, Koomen J, Anasetti C, Dalton W, Perez LE. Stemness of B-cell progenitors in multiple myeloma bone marrow. Clin Cancer Res. 2012 Nov.18(22):6155-6168. Pubmedid: 22988056. Pmcid: PMC3500436.
  • Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, Anasetti C, Weisdorf D, Miller JS. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol. 2012 Nov.189(10):5082-5088. Pubmedid: 23077239. Pmcid: PMC3490031.
  • Anasetti C. The ever elusive permissive mismatch. Biol Blood Marrow Tr. 2012 May.18(5):657-658. Pubmedid: 22449608.
  • Pidala J, Perez L, Beato F, Anasetti C. Ustekinumab demonstrates activity in glucocorticoid-refractory acute GVHD. Bone Marrow Transplant. 2012 May.47(5):747-748. Pubmedid: 21874061.
  • Weisdorf D, Cooley S, Devine S, Fehniger TA, Dipersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J. T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. Biol Blood Marrow Tr. 2012 Jun.18(6):937-943. Pubmedid: 22155505. Pmcid: PMC3319849.
  • Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Brit J Haematol. 2012 Jun.157(5):553-563. Pubmedid: 22449149. Pmcid: PMC4030553.
  • Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E, Kharfan-Dabaja MA, Tomblyn MR, Sullivan DM, Pidala JA, Field TL. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tr. 2012 Jul.18(7):1099-1107. Pubmedid: 22198540.
  • Perkins JB, Shapiro JF, Bookout RN, Yee GC, Anasetti C, Janssen WE, Fernandez HF. Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: clinical and economic outcomes. Am J Hematol. 2012 Jul.87(7):673-677. Pubmedid: 22674468.
  • Anasetti C, Aversa F, Brunstein CG. Back to the future: mismatched unrelated donor, haploidentical related donor, or unrelated umbilical cord blood transplantation?. Biol Blood Marrow Tr. 2012 Jan.18(1 Suppl):S161-S165. Pubmedid: 22226100.
  • Majhail NS, Murphy EA, Denzen EM, Ferguson SS, Ferguson SS, Anasetti C, Bracey A, Burns L, Champlin R, Hubbard N, Markowitz M, Maziarz RT, Medoff E, Neumann J, Schmit-Pokorny K, Weisdorf DJ, Yolin Raley DS, Chell J, Snyder EL. The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: a health care resource and infrastructure assessment. Biol Blood Marrow Tr. 2012 Feb.18(2):172-182. Pubmedid: 22178961.
  • Janssen WE, Rahn D, Hackett M, Coyle D, Tomblyn M, Smilee RC, Anasetti C, Fernandez HF. Apheresis and transplant of hematopoietic progenitor cells (HPC) from allogeneic donors of age above 60 years. Bone Marrow Transplant. 2012 Dec.47(12):1520-1525. Pubmedid: 22562079.
  • Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica. 2012 Dec.97(12):1882-1889. Pubmedid: 22689677. Pmcid: PMC3590095.
  • Yu Y, Yu J, Iclozan C, Kaosaard K, Anasetti C, Yu XZ. Bim is required for T-cell allogeneic responses and graft-versus-host disease in vivo. Am J Blood Res. 2012 Aug.2(1):77-85. Pubmedid: 22432091. Pmcid: PMC3301434.
  • Wang D, Iclozan C, Liu C, Xia C, Anasetti C, Yu XZ. LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice. Biol Blood Marrow Tr. 2012 Aug.18(8):1182-1190.e1. Pubmedid: 22698484. Pmcid: PMC3417119.
  • Kumar A, Mhaskar AR, Reljic T, Mhaskar RS, Kharfan-Dabaja MA, Anasetti C, Mohty M, Djulbegovic B. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia. 2012 Apr.26(4):582-588. Pubmedid: 22182922.
  • Pidala J, Tomblyn M, Nishihori T, Field T, Ayala E, Perkins J, Fernandez H, Locke F, Perez L, Ochoa JL, Alsina M, Anasetti C. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica. 2011 Sep.96(9):1351-1356. Pubmedid: 21565902. Pmcid: PMC3166106.
  • Santarone S, Pidala J, Di Nicola M, Field T, Alsina M, Ayala E, Janssen W, Kharfan-Dabaja MA, Ochoa L, Perez L, Perkins J, Raychaudhuri J, Fernandez H, Anasetti C. Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. Biol Blood Marrow Tr. 2011 Oct.17(10):1505-1511. Pubmedid: 21385623.
  • Pidala J, Lee SJ, Quinn G, Jim H, Kim J, Anasetti C. Variation in management of immune suppression after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tr. 2011 Oct.17(10):1528-1536. Pubmedid: 21440079. Pmcid: PMC4497817.
  • Pidala J, Djulbegovic B, Anasetti C, Kharfan-Dabaja M, Kumar A. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. Cochrane Database Syst Rev. 2011 Oct.(10):CD008818. Pubmedid: 21975786. Pmcid: PMC7386902.
  • Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Ayala E, Perez L, Fernandez H, Fancher K, Tate C, Shaw LM, Milone MC, Gardiner JA, Miller S, Anasetti C. Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. Bone Marrow Transplant. 2011 Nov.46(11):1418-1425. Pubmedid: 21132026.
  • Pidala J, Kim J, Anasetti C, Nishihori T, Betts B, Field T, Perkins J. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica. 2011 Nov.96(11):1678-1684. Pubmedid: 21791465. Pmcid: PMC3208686.
  • Yu Y, Wang D, Liu C, Kaosaard K, Semple K, Anasetti C, Yu XZ. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. Blood. 2011 Nov.118(18):5011-5020. Pubmedid: 21856864. Pmcid: PMC3208306.
  • Perez L, Anasetti C, Pidala J. Have we improved in preventing and treating acute graft-versus-host disease?. Curr Opin Hematol. 2011 Nov.18(6):408-413. Pubmedid: 21912253. Pmcid: PMC3432261.
  • Veerapathran A, Pidala J, Beato F, Yu XZ, Anasetti C. Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. Blood. 2011 Nov.118(20):5671-5680. Pubmedid: 21948174. Pmcid: PMC3217366.
  • Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Field T, Perkins J, Ayala E, Perez L, Fernandez H. Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. Bone Marrow Transplant. 2011 May.46(5):641-649. Pubmedid: 20711242. Pmcid: PMC5726256.
  • Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancetf J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Tr. 2011 Mar.17(3):384-393. Pubmedid: 20655389.
  • Cutler C, Kesselheim A, Gabardi S, Andersson BS, Carpenter P, Khoury HJ, Litzow M, Rowley SD, Lanum S, Leather H, Tina Shih YC, Gale RP, Wingard JR, Appelbaum FR, Anasetti C. Generic immunosuppressants in hematopoietic cell transplantation. Biol Blood Marrow Tr. 2011 Mar.17(3):285-290. Pubmedid: 21087678.
  • Semple K, Yu Y, Wang D, Anasetti C, Yu XZ. Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice. Biol Blood Marrow Tr. 2011 Mar.17(3):309-318. Pubmedid: 21224010. Pmcid: PMC3039088.
  • Semple K, Nguyen A, Yu Y, Wang H, Anasetti C, Yu XZ. Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signaling. Blood. 2011 Mar.117(11):3096-3103. Pubmedid: 21245484. Pmcid: PMC3062312.
  • Woolfrey A, Klein JP, Haagenson M, Spellman S, Petersdorf E, Oudshoorn M, Gajewski J, Hale GA, Horan J, Battiwalla M, Marino SR, Setterholm M, Ringden O, Hurley C, Flomenberg N, Anasetti C, Fernandez-Vina M, Lee SJ. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Tr. 2011 Jun.17(6):885-892. Pubmedid: 20870028. Pmcid: PMC3071866.
  • Pidala J, Kim J, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez H, Anasetti C. Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes. Biol Blood Marrow Tr. 2011 Feb.17(2):239-248. Pubmedid: 20637884. Pmcid: PMC5726258.
  • Pidala J, Roman-Diaz J, Kim J, Nishihori T, Perkins J, Tate C, Ochoa-Bayona JL, Field T, Fernandez HF, Tomblyn M, Ayala E, Anasetti C, Kharfan-Dabaja MA. Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. Int J Hematol. 2011 Feb.93(2):206-212. Pubmedid: 21246311. Pmcid: PMC5718616.
  • Eapen M, Klein JP, Sanz GF, Spellman S, Ruggeri A, Anasetti C, Brown M, Champlin RE, Garcia-Lopez J, Hattersely G, Koegler G, Laughlin MJ, Michel G, Nabhan SK, Smith FO, Horowitz MM, Gluckman E, Rocha V. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol. 2011 Dec.12(13):1214-1221. Pubmedid: 21982422. Pmcid: PMC3245836.
  • Pidala J, Tomblyn M, Nishihori T, Ayala E, Field T, Fernandez H, Perez L, Locke F, Alsina M, Ochoa JL, Perkins J, Tate C, Shapiro J, Conwell M, Bookout R, Anasetti C. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Tr. 2011 Aug.17(8):1237-1244. Pubmedid: 21215811. Pmcid: PMC5735843.
  • Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez HF. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol. 2010 Oct.3:36. Pubmedid: 20925957. Pmcid: PMC2958877.
  • Pidala J, Kim J, Roman-Diaz J, Shapiro J, Nishihori T, Bookout R, Anasetti C, Kharfan-Dabaja MA. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Ann Transplant. 2010 Oct.15(4):21-29. Pubmedid: 21183872.
  • Pidala J, Anasetti C. Glucocorticoid-refractory acute graft-versus-host disease. Biol Blood Marrow Tr. 2010 Nov.16(11):1504-1518. Pubmedid: 20096359.
  • Nishihori T, Perkins J, Kim J, Field T, Pidala J, Roman-Diaz J, Komrokji RS, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution. Am J Hematol. 2010 Nov.85(11):904-907. Pubmedid: 20890908.
  • Pidala J, Kim J, Perkins J, Field T, Fernandez H, Perez L, Ayala E, Kharfan-Dabaja M, Anasetti C. Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant. 2010 May.45(5):919-924. Pubmedid: 19767783.
  • Schriber JR, Anasetti C, Heslop HE, Leahigh AK. Preparing for growth: current capacity and challenges in hematopoietic stem cell transplantation programs. Biol Blood Marrow Tr. 2010 May.16(5):595-597. Pubmedid: 20167277.
  • Kharfan-Dabaja MA, Pidala J, Anasetti C. Thrombotic microangiopathy after GVHD prophylaxis with tacrolimus/sirolimus: a call for use of consensus definition in reporting. Blood. 2010 May.115(21):4316-4317. Pubmedid: 20508174. Pmcid: PMC3374378.
  • Perez LE, Parquet N, Meads M, Anasetti C, Dalton W. Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. Eur J Haematol. 2010 Mar.84(3):212-222. Pubmedid: 19922463.
  • Pidala J, Bloom GC, Enkemann S, Eschrich S, Lancaster J, Anasetti C. Biomarkers to discern transplantation tolerance after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tr. 2010 Jun.16(6):729-738. Pubmedid: 19922809.
  • Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, Perez L, Xu M, Alsina M, Ochoa L, Sullivan D, Janssen W, Anasetti C. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Tr. 2010 Jul.16(7):937-947. Pubmedid: 20102746.
  • Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A, Anasetti C. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010 Feb.45(2):255-260. Pubmedid: 19543327.
  • Iclozan C, Yu Y, Liu C, Liang Y, Yi T, Anasetti C, Yu XZ. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol Blood Marrow Tr. 2010 Feb.16(2):170-178. Pubmedid: 19804837. Pmcid: PMC3876952.
  • Pidala J, Anasetti C, Jim H. Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention. Brit J Haematol. 2010 Feb.148(3):373-385. Pubmedid: 19919651. Pmcid: PMC2810350.
  • Tedeschi SK, Savani BN, Jagasia M, Engelhardt B, Anasetti C, Barrett AJ, Lee S. Time to consider HPV vaccination after allogeneic stem cell transplantation. Biol Blood Marrow Tr. 2010 Aug.16(8):1033-1036. Pubmedid: 20302962. Pmcid: PMC3750708.
  • Hoda D, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout R, Field T, Perez L, Ayala E, Ochoa-Bayona JL, Raychaudhuri J, Alsina M, Greene J, Janssen W, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant. 2010 Aug.45(8):1347-1351. Pubmedid: 19966849.
  • Field T, Anasetti C. Role and timing of hematopoietic cell transplantation for myelodysplastic syndrome. Mediterr J Hematol Infect Dis. 2010 Aug.2(2):e2010019. Pubmedid: 21415970. Pmcid: PMC3033135.
  • Pidala J, Anasetti C. Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse?. Haematologica. 2010 Apr.95(4):660-665. Pubmedid: 20015881. Pmcid: PMC2857197.
  • Spellman S, Bray R, Rosen-Bronson S, Haagenson M, Klein J, Flesch S, Vierra-Green C, Anasetti C. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood. 2010 Apr.115(13):2704-2708. Pubmedid: 20089963. Pmcid: PMC2852369.
  • Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G, Schell MJ, Huang Y, Anasetti C, Perkins J. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant. 2010 Apr.45(4):662-667. Pubmedid: 19684623. Pmcid: PMC2850960.
  • Pidala J, Kim J, Field T, McBride A, Kharfan-Dabaja M, Perkins J, Fernandez H, Perez L, Ayala E, Anasetti C. Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Tr. 2009 Sep.15(9):1116-1121. Pubmedid: 19660725.
  • Pidala J, Anasetti C, Kharfan-Dabaja MA, Cutler C, Sheldon A, Djulbegovic B. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tr. 2009 Nov.15(11):1415-1421. Pubmedid: 19822301.
  • Anasetti C. Selecting donor recipients. Biol Blood Marrow Tr. 2009 Mar.15(3):393-394. Pubmedid: 19203734. Pmcid: PMC4357310.
  • Davies SM, Wang D, Wang T, Arora M, Ringden O, Anasetti C, Pavletic S, Casper J, Macmillan ML, Sanders J, Wall D, Kernan NA. Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. Biol Blood Marrow Tr. 2009 Mar.15(3):360-366. Pubmedid: 19203727. Pmcid: PMC3365559.
  • Ringdén, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C, Cairo MS, Gale RP, Gupta V, Hahn T, Hale GA, Halter J, Jagasia M, Litzow MR, Locatelli F, Marks DI, McCarthy PL, Cowan MJ, Petersdorf EW, Russell JA, Schiller GJ, Schouten H, Spellman S, Verdonck LF, Wingard JR, Horowitz MM, Arora M. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2009 Mar.113(13):3110-3118. Pubmedid: 19059878. Pmcid: PMC2662650.
  • Carnevale-Schianca F, Leisenring W, Martin PJ, Furlong T, Schoch G, Anasetti C, Appelbaum FR, Carpenter PA, Deeg HJ, Kiem HP, Storb R, McDonald GB, Nash RA. Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study. Biol Blood Marrow Tr. 2009 Jun.15(6):749-756. Pubmedid: 19450760. Pmcid: PMC2684865.
  • Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009 Jul.114(1):7-19. Pubmedid: 19336756. Pmcid: PMC2710956.
  • Yu Y, Iclozan C, Yamazaki T, Yang X, Anasetti C, Dong C, Yu XZ. Abundant c-Fas-associated death domain-like interleukin-1-converting enzyme inhibitory protein expression determines resistance of T helper 17 cells to activation-induced cell death. Blood. 2009 Jul.114(5):1026-1028. Pubmedid: 19429865. Pmcid: PMC2721783.
  • Pidala J, Kim J, Anasetti C. Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tr. 2009 Jul.15(7):881-885. Pubmedid: 19539221. Pmcid: PMC4856158.
  • Gajewski JL, LeMaistre CF, Silver SM, Lill MC, Selby GB, Horowitz MM, Rizzo JD, Heslop HE, Anasetti C, Maziarz RT. Impending challenges in the hematopoietic stem cell transplantation physician workforce. Biol Blood Marrow Tr. 2009 Dec.15(12):1493-1501. Pubmedid: 19781658.
  • Salinger DH, Blough DK, Vicini P, Anasetti C, O'Donnell PV, Sandmaier BM, McCune JS. A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients. Clin Cancer Res. 2009 Aug.15(16):5280-5287. Pubmedid: 19671874. Pmcid: PMC2763506.
  • Anasetti C. Chemotherapy or allografting for young adults with high-risk ALL?. Blood. 2008 Jun.111(12):5755. Pubmedid: 18544698.
  • Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C, Setterholm M, Drexler R, Maiers M, King R, Confer D, Klein J. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Tr. 2008 Jul.14(7):748-758. Pubmedid: 18541193. Pmcid: PMC2668157.
  • Liang Y, Liu C, Djeu JY, Zhong B, Peters T, Scharffetter-Kochanek K, Anasetti C, Yu XZ. Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects. Blood. 2008 Jan.111(2):954-962. Pubmedid: 17928532. Pmcid: PMC2200850.
  • Kamani N, Spellman S, Hurley C, Barker J, Smith F, Oudshoorn M, Bray R, Smith A, Williams T, Logan B, Eapen M, Anasetti C, Setterholm M, Confer D. State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants. Biol Blood Marrow Tran. 2008 Jan.14(1):1-6. Pubmedid: 18158954.
  • Perez L, Parquet N, Shain K, Nimmanapalli R, Alsina M, Anasetti C, Dalton W. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. J Immunol. 2008 Feb.180(3):1545-1555. Pubmedid: 18209050.
  • Hahn T, McCarthy PL , Zhang MJ, Wang D, Arora M, Frangoul H, Gale RP, Hale GA, Horan J, Isola L, Maziarz RT, van Rood JJ, Gupta V, Halter J, Reddy V, Tiberghien P, Litzow M, Anasetti C, Pavletic S, Ringden O. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol. 2008 Dec.26(35):5728-5734. Pubmedid: 18981462. Pmcid: PMC2645611.
  • Anasetti C. What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation?. Best Pract Res Clin Haematol. 2008 Dec.21(4):691-697. Pubmedid: 19041609. Pmcid: PMC3470825.
  • Guo F, Iclozan C, Suh WK, Anasetti C, Yu XZ. CD28 controls differentiation of regulatory T cells from naive CD4 T cells. J Immunol. 2008 Aug.181(4):2285-2291. Pubmedid: 18684917. Pmcid: PMC2688779.
  • Ferrara J, Anasetti C, Stadtmauer E, Antin J, Wingard J, Lee S, Levine J, Schultz K, Appelbaum F, Negrin R, Giralt S, Bredeson C, Heslop H, Horowitz M. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. Biol Blood Marrow Tr. 2007 Nov.13(11):1268-1285. Pubmedid: 17950914.
  • Kharfan-Dabaja MA, Anasetti C, Ferrara JL. Sympathectomy protects denervated skin from graft-versus-host disease. Biol Blood Marrow Tran. 2007 Mar.13(3):369-370. Pubmedid: 17317591.
  • Kharfan-Dabaja M, Ayala E, Greene J, Rojiani A, Murtagh F, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant. 2007 Jan.39(2):101-107. Pubmedid: 17143300.
  • Jacobs S, Jacobsen P, Booth-Jones M, Wagner L, Anasetti C. Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients. J Pain Symptom Manag. 2007 Jan.33(1):13-23. Pubmedid: 17196903.
  • Anasetti C, Mulé JJ. To ablate or not to ablate? HSCs in the T cell driver's seat. J Clin Invest. 2007 Feb.117(2):306-310. Pubmedid: 17273553. Pmcid: PMC1783831.
  • Kharfan-Dabaja MA, Ayala E, Greene J, Rojiani A, Murtagh F, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant. 2007 Feb.39(4):253-254. Pubmedid: 17290282.
  • Lee S, Klein J, Haagenson M, Baxter-Lowe L, Confer D, Eapen M, Fernandez-Vina M, Flomenberg N, Horowitz M, Hurley C, Noreen H, Oudshoorn M, Petersdorf E, Setterholm M, Spellman S, Weisdorf D, Williams T, Anasetti C. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007 Dec.110(13):4576-4583. Pubmedid: 17785583.
  • Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ, Wingard JR, Rowley SD, Stroncek D, Gee AP, Horowitz MM, Anasetti C. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Tr. 2007 Dec.13(12):1461-1468. Pubmedid: 18022576. Pmcid: PMC2267869.
  • Kharfan-Dabaja M, Anasetti C, Santos E. Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept. Biol Blood Marrow Tr. 2007 Apr.13(4):373-385. Pubmedid: 17382245.
  • Green M, Anasetti C, Sandin R, Rolfe N, Greene J. Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J Oncol Pharm Pract. 2006 Sep.12(3):179-181. Pubmedid: 17022872.
  • Jones R, Anasetti C, Appel P, Dipersio J, Heslop H, Lemaistre F, Silver S, Sirilla J, Stiff P. ASBMT committee report: white paper on measurement of quality outcomes. Biol Blood Marrow Tr. 2006 May.12(5):594-597. Pubmedid: 16635795.
  • Deeg H, Storer B, Boeckh M, Martin P, McCune J, Myerson D, Heimfeld S, Flowers M, Anasetti C, Doney K, Hansen J, Kiem H, Nash R, O'donnell P, Radich J, Sandmaier B, Scott B, Sorror M, Warren E, Witherspoon R, Woolfrey A, Appelbaum F, Storb R. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Tr. 2006 May.12(5):573-584. Pubmedid: 16635793.
  • Yu X, Albert M, Anasetti C. Alloantigen affinity and CD4 help determine severity of graft-versus-host disease mediated by CD8 donor T cells. J Immunol. 2006 Mar.176(6):3383-3390. Pubmedid: 16517706.
  • Yu X, Liang Y, Nurieva R, Guo F, Anasetti C, Dong C. Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells. J Immunol. 2006 Jun.176(12):7394-7401. Pubmedid: 16751384.
  • Anasetti C. The 2006 BBMT Education Supplement. Biol Blood Marrow Tran. 2006 Jan.12(1):1-1. Pubmedid: 16399576.
  • Farag S, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri M, Boudreau C, Nelson G, Oudshoorn M, van Rood J, Velardi A, Maiers M, Setterholm M, Confer D, Posch P, Anasetti C, Kamani N, Miller J, Weisdorf D, Davies S. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Tr. 2006 Aug.12(8):876-884. Pubmedid: 16864058.
  • Albert M, Anasetti C, Yu X. T regulatory cells as an immunotherapy for transplantation. Expert Opin Biol Ther. 2006 Apr.6(4):315-324. Pubmedid: 16548760.
  • Anasetti C, Perkins J, Nieder M, Field T. Are matched unrelated donor transplants justified for AML in CR1?. Best Pract Res Clin Haematol. 2006.19(2):321-328. Pubmedid: 16516129.
  • Albert M, Liu Y, Anasetti C, Yu X. Antigen-dependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation. Eur J Immunol. 2005 Sep.35(9):2598-2607. Pubmedid: 16078276.
  • Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P, Jerome KA, McCune JS, Storer B, Martin P, Appelbaum F, Abonour R, Westervelt P, Anasetti C. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Tr. 2005 Jun.11(6):465-471. Pubmedid: 15931635.
  • Field T, Anasetti C. Selection of unrelated donors for hematopoietic cell transplantation. Curr Hematol Rep. 2005 Jul.4(4):270-275. Pubmedid: 16009041.
  • Nash R, Johnston L, Parker P, McCune J, Storer B, Slattery J, Furlong T, Anasetti C, Appelbaum F, Lloid M, Deeg H, Kiem H, Martin P, Schubert M, Witherspoon R, Forman S, Blume K, Storb R. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tr. 2005 Jul.11(7):495-505. Pubmedid: 15983549.
  • Albert M, Yu X, Martin P, Anasetti C. Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin. Blood. 2005 Feb.105(3):1355-1361. Pubmedid: 15459004.
  • Yu X, Anasetti C. Memory stem cells sustain disease. Nat Med. 2005 Dec.11(12):1282-1283. Pubmedid: 16333266.
  • Pavletic S, Khouri I, Haagenson M, King R, Bierman P, Bishop M, Carston M, Giralt S, Molina A, Copelan E, Ringden O, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant Research. J Clin Oncol. 2005 Aug.23(24):5788-5794. Pubmedid: 16043827.
  • Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M, Hurley C, Kollman C, Anasetti C, Noreen H, Begovich A, Hildebrand W, Petersdorf E, Schmeckpeper B, Setterholm M, Trachtenberg E, Williams T, Yunis E, Weisdorf D. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004 Oct.104(7):1923-1930. Pubmedid: 15191952.
  • Petersdorf E, Anasetti C, Martin P, Gooley T, Radich J, Malkki M, WoolfreyA, Smith A, Mickelson E, Hansen J. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood. 2004 Nov.104(9):2976-2980. Pubmedid: 15251989.
  • Anasetti C. Advances in the prevention of graft-versus-host disease after hematopoietic cell transplantation. Transplantation. 2004 May.77(9 Suppl):S79-S83. Pubmedid: 15201691.
  • Martin P, McDonald G, Sanders J, Anasetti C, Appelbaum F, Deeg H, NashRA, Petersdorf E, Hansen J, Storb R. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tr. 2004 May.10(5):320-327. Pubmedid: 15111931.
  • Yu XZ, Albert MH, Martin PJ, Anasetti C. CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens. J Clin Invest. 2004 Jun.113(11):1624-1630. Pubmedid: 15173889. Pmcid: PMC419490.
  • Cutler C, Lee S, Greenberg P, Deeg H, Perez W, Anasetti C, Bolwell B, Cairo M, Gale R, Klein J, Lazarus H, Liesveld J, McCarthy P, Milone G, Rizzo J, Schultz K, Trigg M, Keating A, Weisdorf D, Antin J, Horowitz M. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004 Jul.104(2):579-585. Pubmedid: 15039286.
  • Yu XZ, Levin SD, Madrenas J, Anasetti C. Lck is required for activation-induced T cell death after TCR ligation with partial agonists. J Immunol. 2004 Feb.172(3):1437-1443. Pubmedid: 14734719.
  • Stewart B, Storer B, Storek J, Deeg H, Storb R, Hansen J, Appelbaum F, Carpenter P, Sanders J, Kiem H, Nash R, Petersdorf E, Moravec C, Morton A, Anasetti C, Flowers M, Martin P. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004 Dec.104(12):3501-3506. Pubmedid: 15292060.
  • Martin PJ, Pei J, Gooley T, Anasetti C, Appelbaum FR, Deeg J, Hansen JA, Nash RA, Petersdorf EW, Storb R, Ghetie V, Schindler J, Vitetta ES. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Tr. 2004 Aug.10(8):552-560. Pubmedid: 15282533.
  • Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D, Petersdorf E, McSweeney P, Pulsipher M, Woolfrey A, Chauncey T, Agura E, Heimfeld S, Slattery J, Hegenbart U, Anasetti C, Blume K, Storb R. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003 Sep.102(6):2021-2030. Pubmedid: 12791654.
  • Yu X, Martin P, Anasetti C. CD28 signal enhances apoptosis of CD8 T cells after strong TCR ligation. J Immunol. 2003 Mar.170(6):3002-3006. Pubmedid: 12626553.
  • Anasetti C. Acquired tolerance to renal allografts in humans. Am J Transplant. 2003 Mar.3(3):243-244. Pubmedid: 12614276.
  • McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, Schoch HG, Anasetti C, Gooley T. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003 Mar.101(5):2043-2048. Pubmedid: 12406916.
  • Arpinati M, Chirumbolo G, Urbini B, Perrone G, Rondelli D, Anasetti C. Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation. Transpl Immunol. 2003 Jul.11(3-4):345-356. Pubmedid: 12967787.
  • Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Pönisch W, Anasetti C, Woolfrey A, Little MT, Blume KG, McSweeney PA, Storb RF. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce dura. Blood. 2003 Feb.101(4):1620-1629. Pubmedid: 12393457.
  • Deeg H, Gooley T, Flowers M, Sale G, Slattery J, Anasetti C, ChaunceyTR, Doney K, Georges G, Kiem H, Martin P, Petersdorf E, Radich J, SandersJE, Sandmaier B, Warren E, Witherspoon R, Storb R, Appelbaum F. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003 Dec.102(12):3912-3918. Pubmedid: 12920019.
  • Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, Martin PJ, McDonald GB, Nichols WG, Radich J, Woolfrey A, Jenke A, Schleyer E, Thiede C, Ehninger G, Anasetti C. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood. 2003 Aug.102(3):820-826. Pubmedid: 12676781.
  • Anasetti C. Advances in unrelated donor hematopoietic cell transplantation. Haematologica. 2003.88(3):246-249. Pubmedid: 12651260.
  • Hurley C, Baxter Lowe L, Logan B, Karanes C, Anasetti C, Weisdorf D, Confer D. National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants. Biol Blood Marrow Tran. 2003.9(10):610-615. Pubmedid: 14569557.
  • Weisdorf D, Anasetti C, Antin J, Kernan N, Kollman C, Snyder D, Petersdorf E, Nelson G, McGlave P. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002 Mar.99(6):1971-1977. Pubmedid: 11877268.
  • Woolfrey A, Anasetti C, Storer B, Doney K, Milner L, Sievers E, Carpenter P, Martin P, Petersdorf E, Appelbaum F, Hansen J, Sanders J. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood. 2002 Mar.99(6):2002-2008. Pubmedid: 11877272.
  • Koc S, Leisenring W, Flowers M, Anasetti C, Deeg H, Nash R, Sanders J, Witherspoon R, Storb R, Appelbaum F, Martin P. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002 Jul.100(1):48-51. Pubmedid: 12070007.
  • Platzbecker U, Gooley T, Anasetti C, Appelbaum F, Clurman B, Doney K, Chauncey T, Flowers M, Myerson D, Radich J, Storb R, Witherspoon R, Deeg H. Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation. Leuk Lymphoma. 2002 Jul.43(7):1409-1414. Pubmedid: 12389621.
  • Tan P, Mitchell DA, Buss TN, Holmes MA, Anasetti C, Foote J. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J Immunol. 2002 Jul.169(2):1119-1125. Pubmedid: 12097421.
  • Rossi M, Arpinati M, Rondelli D, Anasetti C. Plasmacytoid dendritic cells: do they have a role in immune responses after hematopoietic cell transplantation?. Hum Immunol. 2002 Dec.63(12):1194-1200. Pubmedid: 12480263.
  • Deeg H, Storer B, Slattery J, Anasetti C, Doney K, Hansen J, Kiem H, Martin P, Petersdorf E, Radich J, Sanders J, Shulman H, Warren E, Witherspoon R, Bryant E, Chauncey T, Getzendaner L, Storb R, Appelbaum F. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002 Aug.100(4):1201-1207. Pubmedid: 12149198.
  • Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, Gooley T, Krueger J, Martin P, Pavlovic S, Sanders J, Slattery J, Levitt D, Storb R, Woolfrey A, Anasetti C. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood. 2002 Apr.99(8):2712-2719. Pubmedid: 11929757.
  • Anasetti C. Advances in unrelated donor hematopoietic cell transplantation: improved matching and use of blood stem cells. Haematologica. 2002.87:1-3. Pubmedid: 12412381.
  • Furlong T, Leisenring W, Storb R, Anasetti C, Appelbaum F, Carpenter P, Deeg H, Doney K, Kiem H, Nash R, Sanders J, Witherspoon R, Thompson D, Martin P. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Tr. 2002.8(4):206-212. Pubmedid: 12014809.
  • Jurado M, Deeg H, Storer B, Anasetti C, Anderson J, Bryant E, Chauncey T, Doney K, Flowers M, Hansen J, Martin P, Nash R, Petersdorf E, Radich J, SaleG, Sandmaier B, Storb R, Wade J, Witherspoon R, Appelhaum F. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Tr. 2002.8(3):161-169. Pubmedid: 11939606.
  • Yu X, Anasetti C. Enhancement of susceptibility to Fas-mediated apoptosis of TH1 cells by nonmitogenic anti-CD3epsilon F(ab')2. Transplantation. 2000 Jan.69(1):104-112. Pubmedid: 10653388.
  • Deeg H, Shulman H, Anderson J, Bryant E, Gooley T, Slattery J, Anasetti C, Fefer A, Storb R, Appelbaum F. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood. 2000 Feb.95(4):1188-1194. Pubmedid: 10666189.
  • Arpinati M, Green C, Heimfeld S, Heuser J, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood. 2000 Apr.95(8):2484-2490. Pubmedid: 10753825.
  • Fay JW, Nash RA, Wingard JR, Przepiorka D, Collins RH, Anasetti C, Devine SM, Piñeiro LA, Storb RF, Aro RM. FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation. Transplant P. 1995 Feb.27(1):1374. Pubmedid: 7533383.

Patient Comments
Overall Satisfaction
0
★★★★★
★★★★★

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments